Corpus Intelligence IC Memo — ESKENAZI HEALTH 2026-04-26 09:06 UTC
IC Memo — ESKENAZI HEALTH
Investment Committee Memorandum | IN | 314 beds | Grade C | EBITDA uplift $41.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ESKENAZI HEALTH

CCN 150024 | MARION, IN | 314 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ESKENAZI HEALTH is a 314-bed under-performing / distressed in MARION, IN with $562.3M in net patient revenue and a -59.7% operating margin. The hospital serves a payer mix of 11.8% Medicare, 24.7% Medicaid, and 63.5% commercial.

Thesis: Undervalued. Our ML models identify $41.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -59.7% to -52.3% (+736bps).

Net Revenue HCRIS$562.3M
Current EBITDA COMPUTED$-335.7M
Operating Margin COMPUTED-59.7%
Occupancy HCRIS73.2%
Revenue / Bed COMPUTED$1.8M
Net-to-Gross HCRIS21.3%
Distress Probability ML46.1%

2. Market Context & Competitive Position

171
IN Hospitals
-1.1%
State Median Margin
27
Comparable Hospitals

IN has 171 Medicare-certified hospitals with a median operating margin of -1.1%. The target's margin of -59.7% places it below the state median. Among 27 size-comparable peers (157-628 beds), the median margin is 3.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (157-628), prioritizing same-state peers. 27 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ESKENAZI HEALTH (Target)IN314$562.3M-59.7%
COMMUNITY HEALTH NETWORK INC.IN387$1.24B16.4%
DEACONESS HOSPITALIN545$1.14B0.7%
FRANCISCAN HEALTH INDIANAPOLISIN401$891.4M-0.3%
ASCENSION ST. VINCENT EVANSVILIN346$671.8M11.4%
MEMORIAL HOSPITAL OF SOUTH BENIN429$631.5M9.7%
COMMUNITY HOSPITALIN405$615.1M6.0%
UNION HOSPITAL INC.IN258$581.9M3.8%
LUTHERAN HOSPITAL OF INDIANAIN335$580.1M3.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $41.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$11.8M+210bp18mo
Cost to Collect4.5%2.5%$11.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$11.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$6.8M+122bp9mo
Clean Claim Rate88.0%96.0%$360K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$11.8M
Cost to Collect
$11.2M
Denial Rate Reduction
$11.1M
A/R Days Reduction
$6.8M
Clean Claim Rate
$360K
Total EBITDA Uplift$41.4M
Current EBITDA$-335.7M
+ RCM Uplift+$41.4M
Pro Forma EBITDA$-294.3M
Current Margin-59.7%
Pro Forma Margin-52.3%
WC Released (1x)$21.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-516.4M$-1.80B0.00x-100.0%
Base (11x exit)10.0x11.0x$-516.4M$-2.15B0.00x-100.0%
Bull Case9.0x11.0x$-464.8M$-2.18B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-464.8M$-2.51B0.00x-100.0%
Bear Case11.0x10.0x$-568.1M$-1.84B0.00x-100.0%
Bear (11x exit)11.0x11.0x$-568.1M$-2.21B0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumElevated Medicaid exposure (24.7%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 27 hospitals with 157-628 beds
  • Same-state prioritization (n=28)
  • Comp margins: P25=-1.0% / P50=3.8% / P75=10.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.